-
News | 2022.03.23
Admixture, an adaptation mechanism for populations exposed to pathogens
In a new study, scientists from the Institut Pasteur and the CNRS demonstrate that admixture, a pervasive phenomenon in recent millennia, has enabled human populations to exchange beneficial genetic mutations among themselves, thereby facilitating their adaptation, especially when confronted with infectious diseases.
-
Article | 2022.03.29
PPU-Research & Technology Program
The PPU-Research & Technology Program gives access to a stimulating technological environment to carry out PhD student’s research project. This includes opportunities to conduct technological and methodological co-developments on high-end equipment under the supervision/in partnership with technology platforms or service and research units (UTechS). In addition, students of the PPU-Research...
-
Portrait | 2022.03.29
Jean-Claude Manuguerra: viruses, animals and humans
It all started with a veterinarian and a cross-eyed lionJean-Claude Manuguerra was 7 when he decided that he wanted to become a veterinarian, to "save animals" – like in the TV series Daktari, which he was an avid fan of at the time. In the series, Dr. Marsh Tracy was a vet who cared for local animals and ran the Wameru Study Center for Animal Behavior in Kenya. Marsh Tracy was aided in his day-...
-
Article | 2022.03.29
Strategic and scientific partnership with Université Paris Cité
The Institut Pasteur is a research partner organization, member of Université Paris Cité community. The Institut Pasteur’s association with Université Paris Cité is a global partnership for research and education in the field of biology and health, formally established in June 2021.
-
Document de presse | 2022.03.25
Towards more effective treatments for immunocompromised patients
For severely immunocompromised patients, a bone marrow transplant restores immune defenses and allows them to resume normal life. But after observing the nasopharyngeal mucosa, one of the body's first lines of immune defense, scientists from the Institut Pasteur, Université Paris Cité, Inserm and the Paris Public Hospital Network (AP-HP), in collaboration with the Imagine Institute, demonstrated...
-
Document de presse | 2022.03.29
SARS-CoV-2: neutralization of BA.1 and BA.2 by therapeutic monoclonal antibodies
The SARS-CoV-2 Omicron BA.1 sublineage has been supplanted in many countries by the BA.2 sublineage. Although Omicron is responsible for less severe forms in the general population, immunocompromised people are still at higher risk of developing severe forms of COVID-19. Several monoclonal antibodies are currently available in clinical practice as a preventive treatment for these patients....
-
Document de presse | 2022.04.13
Colon cancer: how mutation of the APC gene disrupts lymphocyte migration
In patients with familial adenomatous polyposis, a genetic disease predisposing to colon cancer, mutations of the APC gene induce the formation of intestinal polyps, but also reduce immune system activity. In a new study, researchers from the Institut Pasteur, INSERM(1) and Université Paris Cité describe the mechanisms that modify the structure of T lymphocytes and hinder their migration towards...
-
Document de presse | 2022.04.20
When severe infection causes long-term mood disorders: A promising avenue to prevent mental illness following a transient infection
The brain is able to detect and regulate localized or systemic inflammation by using two communication pathways. The first, humoral, makes use of specific brain structures that enable circulating inflammatory mediators to enter the brain. The second, neural, involves nerves whose sensory afferents transmit the inflammatory signal detected at local level. The vagus nerve therefore uses identified...
-
Document de presse | 2022.04.12
HIV: The Antibodies of "Post-treatment Controllers"
A very small percentage of people with HIV-1, known as "post-treatment controllers" (PTCs), are able to control their infection after interrupting all antiretroviral therapy.Understanding the fundamental mechanisms that govern their immune response is essential in order to develop HIV-1 vaccines, novel therapeutic strategies to achieve remission, or both.A recent study investigated the humoral...
-
News | 2022.04.14
Monoclonal antibody SPK001: potent and broad neutralization activity across all SARS-CoV-2 variants of concern
SPK001, the monoclonal antibody developed by SpikImm, a biotech company founded by the Institut Pasteur and Truffle Capital, has demonstrated a potent and broad neutralization activity across all SARS-CoV-2 variants of concern, including omicron (BA.1 and BA.2). Originally developed in the Humoral Immunology lab headed by Dr Hugo Mouquet at the Institut Pasteur (joint research unit Inserm),...
